Correction: Comprehensive review of CRISPR‑based gene editing: mechanisms, challenges, and applications in cancer therapy

Mohammad Chehelgerdi^{1

2}, Matin Chehelgerdi^{3

4}, Milad Khorramian-Ghahfarokhi⁵, Marjan Shafieizadeh⁶, Esmaeil Mahmoudi⁴, Fatemeh Eskandari⁷, Mohsen Rashidi^{8

9}, Asghar Arshi¹⁰, Abbas Mokhtari-Farsani^{3

11}

Affiliations

¹ Novin Genome (NG) Lab, Research and Development Center for Biotechnology, Shahrekord, Iran. Chehelgerdi1992@gmail.com.
² Young Researchers and Elite Club, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran. Chehelgerdi1992@gmail.com.
³ Novin Genome (NG) Lab, Research and Development Center for Biotechnology, Shahrekord, Iran.
⁴ Young Researchers and Elite Club, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran.
⁵ Division of Biotechnology, Department of Pathobiology, School of Veterinary Medicine, Shiraz University, Shiraz, Iran.
⁶ Department of Chemistry, Shahid Bahonar University of Kerman, Kerman, Iran.
⁷ Faculty of Molecular and Cellular Biology ‑Genetics, Islamic Azad University of Falavarjan, Isfahan, Iran.
⁸ Department Pharmacology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
⁹ The Health of Plant and Livestock Products Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
¹⁰ Young Researchers and Elite Club, Najafabad Branch, Islamic Azad University, Najafabad, Iran.
¹¹ Department of Biology, Nourdanesh Institute of Higher Education, Meymeh, Isfahan, Iran.

Published Erratum

Mohammad Chehelgerdi et al. Mol Cancer. 2024.

. 2024 Feb 27;23(1):43.

doi: 10.1186/s12943-024-01961-9.

¹ Novin Genome (NG) Lab, Research and Development Center for Biotechnology, Shahrekord, Iran. Chehelgerdi1992@gmail.com.
² Young Researchers and Elite Club, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran. Chehelgerdi1992@gmail.com.
³ Novin Genome (NG) Lab, Research and Development Center for Biotechnology, Shahrekord, Iran.
⁴ Young Researchers and Elite Club, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran.
⁵ Division of Biotechnology, Department of Pathobiology, School of Veterinary Medicine, Shiraz University, Shiraz, Iran.
⁶ Department of Chemistry, Shahid Bahonar University of Kerman, Kerman, Iran.
⁷ Faculty of Molecular and Cellular Biology ‑Genetics, Islamic Azad University of Falavarjan, Isfahan, Iran.
⁸ Department Pharmacology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
⁹ The Health of Plant and Livestock Products Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
¹⁰ Young Researchers and Elite Club, Najafabad Branch, Islamic Azad University, Najafabad, Iran.
¹¹ Department of Biology, Nourdanesh Institute of Higher Education, Meymeh, Isfahan, Iran.

No abstract available

Erratum for

Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy.
Chehelgerdi M, Chehelgerdi M, Khorramian-Ghahfarokhi M, Shafieizadeh M, Mahmoudi E, Eskandari F, Rashidi M, Arshi A, Mokhtari-Farsani A. Chehelgerdi M, et al. Mol Cancer. 2024 Jan 9;23(1):9. doi: 10.1186/s12943-023-01925-5. Mol Cancer. 2024. PMID: 38195537 Free PMC article. Review.

1. Chehelgerdi M, Chehelgerdi M, Khorramian-Ghahfarokhi M, et al. Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy. Mol Cancer. 2024;23:9. doi: 10.1186/s12943-023-01925-5. - DOI - PMC - PubMed
1. Liu Q. World-first phase I clinical trial for CRISPR-Cas9 PD-1-edited T-cells in advanced nonsmall cell lung cancer. Glob Med Genet. 2020;7:073–74. doi: 10.1055/s-0040-1721451. - DOI - PMC - PubMed
1. Zhen S, Li X. Oncogenic human papillomavirus: application of CRISPR/Cas9 therapeutic strategies for cervical cancer. Cell Physiol Biochem. 2018:2455–66. - PubMed
1. Lu Y, Xue J, Deng T, Zhou X, Yu K, Deng L, et al. Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer. Nat Med. 2020;26:732–740. doi: 10.1038/s41591-020-0840-5. - DOI - PubMed
1. Ottaviano G, Georgiadis C, Gkazi SA, Syed F, Zhan H, Etuk A, et al. Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia. Sci Transl Med. 2022;14. - PubMed